Series B Insurance Program Restructure

The Series A insurance program rarely scales cleanly to Series B. The coverage that worked at the smaller stage typically needs structural restructuring rather than incremental limit increases. Companies that treat Series B insurance as a renewal exercise find themselves with material gaps that surface either at the next round of diligence or in a claim event. Companies that approach Series B as a program redesign tend to land with substantially better terms and structure for the growth-stage operating environment they are now in.

This walks through what specifically changes between Series A and Series B, where the structural decisions need attention, and what the underwriting conversation looks like at this stage. For the Series A starting point, see What insurance does a digital health startup need to raise a Series A?. Series B is one point on a longer path mapped in insurance at each funding stage.

Why Series B Is a Restructure

Several factors combine to make Series B a restructuring point rather than an incremental change point.

Headcount and operational scale. Series B typically takes the company past 50 to 100 employees and into multistate operations. The EPLI exposure crosses thresholds that require dedicated attention.

Regulatory maturation. FDA clearance may have occurred, CLIA certification is in place, BAA volume has multiplied, and HIPAA exposure has grown. The regulatory dimension of the program is now substantive.

Board complexity. Multiple institutional investors, multiple independent directors, and committee structure produce D&O exposure that the Series A tower may not adequately address.

Capital structure and disclosure. Larger investor base, more public disclosure, and increasing forward-looking claims produce securities risk that scales the D&O tower.

International operations. Series B is frequently the stage at which international expansion begins, introducing parallel regulatory and insurance frameworks.

Commercial operations. For companies that have launched commercial products, the products liability, recall, and post-market exposure surface scales materially.

The program that satisfied Series A diligence does not satisfy Series B diligence. The investors at Series B are doing more thorough work and expect a more developed coverage structure.

D&O Tower Restructure

The single most substantive change at Series B is typically the D&O restructure. For the broader stage-by-stage framing, see D&O Insurance for Life Sciences Companies: A Stage-by-Stage Guide.

The Series A D&O is often a single primary placement with Side A separation. At Series B, several structural shifts happen.

Tower structure with excess layers. A single primary placement scales by adding excess layers, structured to match the round size and the disclosure exposure. Multi-layer towers introduce coordination questions across carriers, follow-form considerations, and the question of which carriers provide adequate Side A capacity.

Dedicated Side A capacity. At Series A, Side A is often included in the primary. At Series B, dedicated Side A capacity (sometimes a Difference in Conditions / Difference in Limits policy) becomes standard. The institutional directors require this structure as exposure grows.

Management liability separation. EPLI and fiduciary liability that packaged with D&O at Series A often separate into discrete placements at Series B. The combined management liability product that was efficient at smaller scale frequently becomes the wrong structure.

Securities risk maturation. The Side C coverage scales with the company’s disclosure profile and the volume of forward-looking statements. Companies that have made specific commitments about clinical trial readouts, regulatory milestones, or commercial readiness carry materially more securities risk at Series B than at Series A.

Pre-IPO considerations begin. For companies on a public offering trajectory, the conversation about pre-IPO D&O structure starts at Series B even though the actual placement is later.

EPLI Often Emerges as a Distinct Line

EPLI was often packaged with D&O at Series A. At Series B, it typically becomes its own placement. For the standalone EPLI framing, see EPLI for Life Sciences Companies: When You Need It and What Coverage Should Include.

The reasons for separation at Series B include the headcount crossing into the range where EPLI claim frequency is meaningful, the need for industry-specific endorsements (clinical staff, sales representatives, laboratory technicians, regulatory affairs personnel), the wage and hour sub-limit scaling, and the operational separation of HR risk from board-level D&O risk.

The structural decisions at Series B include the wage and hour sub-limit calibration, the third-party EPLI extension for field-based operations, the international employee coverage where applicable, and the coordination between EPLI and D&O for executive-level employment decisions.

Cyber Program Maturation

Cyber at Series A frequently addresses the basic exposure: first-party breach response, regulatory defense, and BI. At Series B, the cyber program typically restructures to address several maturation factors.

BAA volume and complexity. Series B HIPAA-regulated companies often carry dozens or hundreds of BAAs. The contractual liability exposure scales accordingly.

OCR enforcement posture. The Risk Analysis Initiative, with 50+ enforcement actions completed and an expansion to risk management, means regulatory defense limits need to be calibrated to current enforcement levels.

Vendor concentration. Cloud providers, EHR vendors, billing platforms, and clearinghouse relationships create contingent BI exposure that scales with operational complexity.

Controls maturation. SOC 2 Type II is now the baseline expectation. MFA, encryption, and segmentation are presumed. The cyber underwriting conversation at Series B is about how well the controls are implemented, not whether they exist.

Anticipated Security Rule changes. The December 2024 NPRM proposing changes to the HIPAA Security Rule, if finalized, would require mandatory MFA, universal encryption, and annual risk analysis. Specialty cyber carriers are already pricing as if the controls are required. For the broader cyber framing, see Cyber Insurance for HIPAA-Regulated Companies.

The structural decisions at Series B include the regulatory defense sub-limit calibration, the BAA liability sub-limit, the BI and contingent BI structure, and the cyber crime sub-limit relative to operational exposure.

International Coverage Considerations

Series B is frequently the stage at which international operations begin. The insurance dimension of international expansion has several substantive components.

Statutory coverage in operating countries. Workers’ compensation equivalents, employer’s liability, and similar local requirements vary by jurisdiction and require local placement.

Local product liability and professional liability. US-based products and professional coverage may not extend to operations in EU, APAC, or other jurisdictions. Local placements may be required.

EU MDR implications. For medical device companies CE-marking in the EU, the EU MDR vigilance framework (Articles 87-91) introduces obligations that interact with US recall and post-market coverage. For the recall framing, see Recall Coverage for Medical Device Manufacturers.

GDPR and data privacy frameworks. EU operations introduce GDPR exposure that runs parallel to HIPAA in the US. Cyber coverage needs international extension or local placement.

Foreign Voluntary Workers Compensation (FVWC). For US employees traveling internationally for business purposes, FVWC extensions become relevant.

Kidnap, ransom, and extortion (KRE). For companies operating in higher-risk regions or with executives traveling internationally, KRE becomes a real consideration.

Products Liability and Recall at Series B

For commercial-stage life sciences companies, the products liability and recall coverage at Series B typically restructures.

Limit calibration to commercial scale. Products limits at clinical-trial scale frequently do not match commercial-scale exposure. Series B is often where the program scales.

Recall coverage maturation. The basic recall sub-limit that satisfied the Series A check-the-box review needs structural attention at Series B. Business interruption and brand rehabilitation sub-limits, third-party recall, and the interaction with products liability all need explicit attention. For recall depth, see Recall Coverage for Medical Device Manufacturers.

Post-market surveillance integration. QMSR (effective February 2, 2026) raised the documentation bar on post-market surveillance. The insurance program now interacts with these systems for claim notice, recall triggers, and regulatory action documentation.

Tech E&O and Professional Liability Scaling

For SaaS-component life sciences companies and SaMD operators, Tech E&O at Series B typically scales beyond the Series A structure.

The maturation factors include enterprise customer concentration that creates contractual liability, AI/ML capabilities that introduce explainability and decision-impact exposure, integration with EHR or other regulated systems that produce downstream exposure, and the international customer base where applicable.

For SaMD specifically, the Tech E&O / products liability coordination at Series B becomes a substantive structural item. See What insurance does an FDA-regulated SaMD company need?.

The Series B Underwriting Conversation

The Series B placement conversation has a different cadence than the Series A version. Three patterns recur.

Carriers want updated regulatory documentation. FDA correspondence current to the placement date, OCR communications and any state agency matters, BAA inventory, SOC 2 attestation, and quality management system documentation. The package is more substantive than the Series A version and the review takes longer.

Carriers ask about commercial milestones explicitly. Forward-looking statements about clinical trial readouts, clearance timelines, commercial launches, and revenue projections feed into the D&O underwriting. Companies that have made specific commitments and met them sit better than companies with a history of missed milestones.

Carriers scrutinize the broker relationship. At Series A, the broker’s market access may have been adequate to place the program at scale. At Series B, the specialty market relationships matter more. Carriers writing the Series B program want to see that the broker can manage the multi-layer, multi-line program at the operational complexity Series B introduces.

Placement timeline is longer. A Series A program can sometimes be placed in 30 to 45 days. A Series B program typically requires 60 to 90 days for a clean placement that runs underwriting on the merits rather than under deadline pressure.

The renewal conversation starts immediately. Once the Series B program binds, the renewal conversation is already underway. Carriers want to see how the company performs against its operational plan during the policy period, and the renewal terms reflect that performance.

What Diligence Looks Like at Series B

Series B investor counsel does more thorough insurance diligence than Series A counsel. The review typically includes a full coverage summary, loss runs from each carrier, BAA inventory verification for HIPAA-regulated targets, regulatory correspondence review (Warning Letters, 483s, OCR communications, state AG matters), and a structural review of the D&O tower.

The gaps that surface at Series B diligence are different from Series A. Companies that scaled the Series A program incrementally rather than restructuring find themselves with:

A D&O primary that no longer matches round size. Most common Series B diligence flag.

EPLI inadequacy at higher headcount. Particularly for companies in California, New York, and other state law-elevated jurisdictions.

Cyber regulatory defense calibrated to pre-2024 OCR levels. Investors now know what current enforcement looks like.

Missing international extensions. For companies that expanded internationally between rounds.

Products and recall limits at clinical scale for now-commercial operations. A timing issue that compounds.

What investor counsel actually checks during diligence is mapped in what insurance a life sciences company needs during due diligence.

A Note on Placement

MedTech Coverage works with life sciences companies on Series B program restructures across digital health, medical device, and clinical lab segments. Coverage is placed through Tower Street Insurance’s appointments with the specialty markets that write the full program structure at growth stage.

If a Series B is approaching and the existing program needs to be evaluated against the structural changes the round will trigger, a coverage review produces a working document mapped to the company’s current and post-round operational and regulatory profile.